Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis
Weiwei Zhu,
Chunquan Liu,
Chunting Tan,
Jie Zhang
Affiliations
Weiwei Zhu
Department of Pulmonary and Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, China
Chunquan Liu
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, China
Chunting Tan
Department of Pulmonary and Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, China; Corresponding author. Department of Pulmonary and Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Beijing, Xicheng District, 100050 China.
Jie Zhang
Department of Pulmonary and Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, China; Corresponding author. Department of Pulmonary and Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Beijing, Fengtai District, 100070 China.
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial disease that cannot be cured, and treatment options for IPF are very limited. Early diagnosis, close monitoring of disease progression, and timely treatment are therefore the best options for patients due to the irreversibility of IPF. Effective markers help doctors judge the development and prognosis of disease. Recent research on traditional biomarkers (KL-6, SP-D, MMP-7, TIMPs, CCL18) has provided novel ideas for predicting disease progression and prognosis. Some emerging biomarkers (HE4, GDF15, PRDX4, inflammatory cells, G-CSF) also provide more possibilities for disease prediction. In addition to markers in serum and bronchoalveolar lavage fluid (BALF), some improvements related to the GAP model and chest HRCT also show good predictive ability for disease prognosis.
